Hear from Drs. Danzig and Sheth about the clinical trial and real-world evidence showing that some patients with retinal disease may benefit from the port delivery system with ranibizumab, a surgical implant that allows for longer treatment intervals compared to second-generation intravitreal injections.
Comprehensive Strategies for Managing Retinal Disease
Media formats available:
Details
Presenters
Target Audience
This certified CME activity is designed for retina specialists who care for patients with retinal diseases.
Grantor Statement
This activity is supported by an independent educational grant from Genentech, a member of the Roche Group.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Review the treatment burden associated with anti-VEGF injections
- Summarize treatment advances designed to improve durability of therapeutic effect in patients with neovascular age-related macular degeneration and diabetic eye disease
- Evaluate the efficacy, durability, and patient outcomes associated with surgical implants
- Describe best practices for using surgical implants to treat retinal diseases
- Formulate an action plan for managing complications associated with surgical implants
Accreditation and Credit Designation Statements
Provided by Evolve Medical Education
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 0.25 AMA PRA Category Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Faculty
Veeral Sheth, MD, MBA, FASRS, FACS (Chair)
Director of Clinical Research
University Retina and Macula Associates
Board Certified Ophthalmologist and Retinal Surgeon
Clinical Assistant Professor
University of Illinois at Chicago
Chicago, IL
Carl J. Danzig, MD, FASRS
Director of Vitreoretinal Services and Retina Clinical Research
Rand Eye Institute
Deerfield Beach, FL
Affiliate Assistant Professor of Clinical Biomedical Science
Florida Atlantic University
Charles E. Schmidt College of Medicine
Boca Raton, FLDisclosure of Relevant Financial Relationships
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.Veeral S. Sheth, MD, MBA, FASRS, FACS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alkeus, Apellis, Boehringer Ingelheim, EyePoint Pharmaceuticals, Genentech, Iveric Bio, Janssen, Kriya Therapeutics, Novartis, Ocular Therapeutix, Oculis, Ocuphire, Ollin Biosciences, Opthea, Regeneron, RevOpsis, Unity, and Vial. Grant/Research Support: 4DMT, AbbVie, Adverum Biotechnologies, Alimera Sciences, Ashvattha Therapeutics, Astellas, Aviceda, Chengdu Kanghong, Eluminex Biosciences, Eyebiotech, Eyepoint Pharmaceuticals, Genentech, Gyroscope Therapeutics, i-Lumen Scientific, Ionis, Iveric Bio, Janssen Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Oculus, Ocugen, OcuTerra, Olix, Opthea, Outlook, Oxular, Oxurion, Perfuse Therapeutics, Recens Medical, Regeneron, Regenxbio, Rezolute, Roche, SalutarisMD, SamChungDang, Santen, Smilebiotek, Unity Biotechnology, and Vanotech. Speaker's Bureau: Genentech and Iveric Bio.
Carl J. Danzig, MD, FASRS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: 4DMT, AbbVie, Adverum Biotechnologies, Alimera Sciences, EyeBio, Galimedix Therapeutics, Genentech, Iveric Bio/Astellas, Kodiak Sciences, Novartis, Ocular Therapeutix, Oculis, Ocuphire Pharma, Opthea, Regeneron, Regenxbio, Roche, Samsung Bioepsis, and Stealth BioTherapeutics. Grant/Research Support: 4DMT, Adverum Biotechnologies, Alexion, Annexon Biosciences, Aviceda, Bayer, Cognition, Curacle, EyeBio, Genentech, Gyroscope Therapeutics, Iveric Bio/Astellas, Kodiak Sciences, Novartis, Ocular Therapeutix, Oculis, Regeneron, Regenxbio, Rezolute, Roche, and Unity Biotechnology. Speaker's Bureau: Genentech and Iveric Bio/Astellas.
The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Genentech, a member of the Roche Group. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Luis A. Gonzalez, MD, MPH
Jeremiah Brown Jr., MD, MS, FASRS
- CME/CE Broadcast Replay
Eye on the Target: Navigating Ocular Challenges With ADC Cancer Therapies
1.00 creditKathleen N. Moore, MD, MS, FASCO
Aaron Samuel Gold, OD, FAAO
Carlo J. Pelino, OD, FAAO
Aaron Samuel Gold, OD, FAAO
Timothy G. Murray, MD, MBA, FASRS
Paul Petrakos, DO, MS
I. Paul Singh, MD
